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Abstract
Background: It is well known that brain dopamine (DA) signals support risk-based decision making; however, the 
specific terminal regions of midbrain DA neurons through which DA signals mediate risk-based decision making are 
unknown.
Methods: Using microinfusions of the D1/D2 receptor antagonist flupenthixol, we sought to explore the role of D1/D2 receptor 
activity in the rat orbitofrontal cortex (OFC) and core and shell regions of the nucleus accumbens (AcbC and AcbS, respectively) 
in the regulation of risky choices. A risk-discounting task was used that involves choices between a certain small-reward 
lever that always delivered 1 pellet or a risky large-reward lever which delivered 4 pellets but had a decreasing probability of 
receiving the reward across 4 subsequent within-session trial blocks (100%, 50%, 25%, 12.5%). To validate task sensitivity to 
experimental manipulations of DA activity, we also examined the effects of systemic amphetamine and flupenthixol.
Results: Systemic amphetamine increased while systemic flupenthixol reduced risky choices. Results further demonstrate 
that rats that received intra-AcbC flupenthixol were able to track increasing risk associated with the risky lever but displayed 
a generally reduced preference for the risky lever across all trial blocks, including in the initial trial block (large reward at 
100%). Microinfusions of flupenthixol into the AcbS or OFC did not alter risk-based decision making.
Conclusions: Our data suggest that intra-AcbC D1/D2 receptor signaling does not support the ability to track shifts in reward 
probabilities but does bias risk-based decision making. That is, it increased the rats’ preference for the response option 
known to be associated with higher risk-related costs.
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Introduction
For adaptive decision making in an uncertain and ever-changing 
environment, animals often have to analyze expected costs and 
benefits of the available response options, as for instance the 
probability and magnitude of rewards associated with alterna-
tive courses of action. The capacity to assess the probability 
(risk) of receiving rewards relies on a complex neural network 
including the medial prefrontal cortex (mPFC), orbitofron-
tal cortex (OFC), core and shell regions of the nucleus accum-
bens (AcbC and AcbS, respectively), and basolateral amygdala 
(BLA; Cardinal, 2006; Roitman and Roitman, 2010; Stopper 
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and Floresco, 2011; Zeeb and Winstanley, 2011; Abela and 
Chudasama, 2013; Morgado et  al., 2014). For instance, electro-
physiological studies revealed neurons within the OFC that code 
information about reward risk, defined as variance in the spread 
of outcomes (O’Neill and Schultz, 2010). Moreover, inactivation 
of the mPFC, the AcbC/AcbS, or BLA altered the preference for 
the risky reward relative to the certain reward in probabilis-
tic tasks in which risk refers to choice situations with known 
distributions of potential reward related to particular actions 
(Cardinal and Howes, 2005; Ghods-Sharifi et al., 2009; St Onge 
and Floresco, 2010; Stopper and Floresco, 2011). A considerable 
body of evidence suggests that the mesocorticolimbic dopamine 
(DA) system supports risk-based decision making. For instance, 
midbrain DA neurons are activated by stimuli predicting risky 
rewards and generate a neuronal signal that varies monotoni-
cally with risk (Fiorillo et al., 2003). Such DA risk signals may have 
several functions: they could provide input to brain structures 
involved in the evaluation of reward and risk and serve as teach-
ing signals to enhance learning (Schultz, 2010). Furthermore, 
there is evidence that DA receptor expression patterns can pre-
dict risk bias: lower striatal D2 receptor mRNA expression in a 
subgroup of adolescent rats with greater risk-taking correlates 
with greater cocaine self-administration in adulthood (Mitchell 
et al., 2014). Moreover, drug-induced manipulations of DA activ-
ity affect risk-based decision making. For instance, sustained 
alcohol intake can alter risk-based decision making in rats by 
compromising DA signaling of risk (Nasrallah et al., 2011).
Terminal regions of midbrain DA neurons, through which DA 
signals mediate risk-based decision making, have been iden-
tified in part. For instance, mPFC DA receptors contribute in a 
dissociable manner to risk-based decision making: an intra-
mPFC D1-receptor blockade reduced risky choices whereas 
an intra-mPFC D2-receptor blockade increased them (St Onge 
et al., 2011). Moreover, a previous receptor type–specific analy-
sis revealed that a D1, but not D2, receptor blockade within the 
whole Acb reduced risky choices (Stopper et al., 2013).
The role of DA signals in the AcbC, AcbS, and OFC in risk-
based decision making remains to be addressed. Therefore, by 
means of a probabilistic choice task used in previous work (St 
Onge et al., 2010), the present study sought to explore whether 
D1/D2 receptor activity in the AcbC, AcbS, or OFC supports 
risk-based decision making using local microinfusions of flu-
penthixol. To validate task sensitivity to experimental manipu-
lations of DA activity, we also examined the effects of systemic 
amphetamine and flupenthixol, two prototypical DAergic drugs 
with prominent effects on risky choice.
Methods
All animal experiments were performed according to the 
German Law on Animal Protection and approved by the proper 
authorities.
Experiment 1: Effects of Flupenthixol and 
Amphetamine on Risky Choice
Subjects
Male Lister hooded rats (Charles River) weighting between 
200 and 225 g upon arrival were used. They were housed in 
transparent plastic cages (60 cm × 38 cm × 20 cm, Tecniplast) 
in groups of up to four animals. Rats had a 12:12-h light-dark 
cycle (lights on at 07:00) with ad libitum access to water. Upon 
arrival, standard laboratory chow (Altromin) was given ad libi-
tum for at least 5 days. To maintain rats at approximately 85% of 
their free-feeding weight, food was restricted to 15 g per animal 
per day. For environmental enrichment, a plastic tube (20 cm, Ø 
12 cm) was fixed on the lid of each cage. Temperature (22 ± 2°C) 
and humidity (50 ± 10%) were kept constant in the animal house.
Apparatus, Habituation, and Lever Press Training
Training and testing took place in identical operant chambers 
(24 x 21 x 30 cm; Med Associates), which were surrounded by 
sound attenuating cubicles (for details see Supplementary 
Material). Habituation and lever press training was as described 
in Mai and Hauber (2012; see also Supplementary Material). 
After termination of lever press training, the risk-discounting 
task was introduced.
Risk Discounting Task
The risk-discounting task used here was based on proto-
cols described by Cardinal and Howes (2005) and St Onge and 
Floresco (2009). For each animal, one of the two levers was 
designated as being the certain small-reward lever and the 
other therisky large-reward lever. This assignment remained 
constant for each animal throughout the study and was coun-
terbalanced across rats. Choice of the certain lever always deliv-
ered one pellet and choice of the risky lever had a probabilistic 
delivery of four or no pellets. The probabilistic delivery of the 
risky lever changed in the course of the daily sessions. The task 
is described in detail in the Supplementary Material. A  sche-
matic of a single free-choice trial in the risk-discounting task is 
given in Figure 1.
Effects of D-Amphetamine and Flupenthixol: Behavioral 
Procedures
Animals were trained on the risk-discounting task for 15 days 
before the effects of d-amphetamine and flupenthixol on risk 
discounting were assessed. Different doses of d-amphetamine 
hemisulfate salt (Sigma Aldrich) and cis-(Z)-Flupenthixol 
dihydrochloride (Sigma Aldrich) were investigated in two 
Figure  1. Schematic of a single free-choice trial in the risk-discounting task. 
Choice of the certain lever always led to delivery of one pellet, while choice of 
the risky lever led to delivery of 4 pellets with decreasing probabilities across 
trial blocks (p = 1.0, 0.5, 0.25, 0.125).
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subsequent experiments. In the first experiment, higher drug 
doses (amphetamine 2 mg/kg, flupenthixol 0.4 mg/kg vs. saline 
1 ml/kg) were tested; in the second experiment, lower drug 
doses (amphetamine 0.5 mg/kg, flupenthixol 0.25 mg/kg vs. 
saline 1 ml/kg) were tested. Drugs were dissolved in physiologi-
cal saline and administered intraperitoneally at a volume of 
1 ml/kg. After administration rats were returned to their home 
cages for 30 min (amphetamine), 45 min (saline), or 60 min (flu-
penthixol) until behavioral testing. A within-subject design was 
used in each experiment, with the order of drug administration 
pseudo-randomized across rats. Drugs (saline, amphetamine, 
flupenthixol) in each experiment were tested in two subsequent 
4-day blocks (see Supplementary Material).
Data Analysis and Statistics
Percentage choices of the risky reward lever are given as means 
± standard error of the mean (SEM). Data were subjected to a 
repeated-measures analysis of variance (ANOVA) with two 
within-subject factors (treatment and large reward probabil-
ity). As a within-subject protocol was used for each experiment, 
all rats received all treatments in a randomly varied order. All 
statistical computations were carried out with STATISTICA TM 
(version 7.1, StatSoft, Inc.). The level of statistical significance 
(α-level) was set at p ≤ 0.05 (α-levels > 0.05 were designated as 
n.s., not significant).
Experiment 2: Effects of AcbC Flupenthixol on 
Risky Choice
In Experiment 2, animals were trained on the risk-discount-
ing task until they reached the defined learning criterion as 
described in Experiment 1. Thereafter, animals were implanted 
with cannulae directed to the AcbC using standard stereotaxic 
procedures (see Supplementary Material). The following coordi-
nates were chosen with reference to the atlas of Paxinos and 
Watson (1998): anterioposterior (AP) +1.2 mm; mediolateral (ML) 
±1.8 mm; dorsoventral (DV) -7.0 mm. After recovery, effects of 
flupenthixol microinfusions on risky choices were assessed. 
We conducted further analyses of behavioral data to obtain 
more detailed information as to how this treatment could have 
induced changes in risky choices (see Supplementary Material).
Microinfusion Procedure
Two doses of flupenthixol (15; 17.5 µg) were examined in two 
subsequent tests. A  within-subject design was used where 
the order of drug (cis-(Z)-flupenthixol dihydrochloride; Sigma 
Aldrich) and saline microinfusion was counterbalanced for 
each rat. The sample size in the first test (flupenthixol 15 µg) 
was n = 13 and in the second test (flupenthixol 17.5 µg) n = 10, 
because three rats were excluded due to occluded guide can-
nulae. Microinfusions (procedure, see Supplementary Material) 
were separated by risk-discounting task-training days without 
microinfusions. Doses refer to previous studies demonstrating 
behavioral effectiveness after intra-AcbC infusion (Moscarello 
et al., 2010; Saunders and Robinson, 2012).
Histology
After completion of the behavioral testing, animals were eutha-
nized by an overdose of isoflurane (Abbott) to control for correct 
cannula placements. Brains were removed, fixed in 4% formalin 
for 24 h, and stored in 30% glucose. Brains were frozen and coro-
nal brain sections (35–40 µm) were collected, mounted on coated 
slides, and stained with cresyl violet. Placements of guide can-
nulas were verified with reference to the atlas of Paxinos and 
Watson (1998).
Experiment 3: Effects of AcbS Flupenthixol on 
Risky Choice
Unless noted otherwise, the same procedures as described in 
Experiment 2 were used. Animals were implanted with cannu-
lae directed to the AcbS (AP +1.2 mm; ML ±0.9 mm; DV -7.0 mm; 
Paxinos and Watson, 1998) and, after recovery, the effects of 
flupenthixol (17.5  µg) microinfusions on risky choices were 
assessed.
Experiment 4: Effects of OFC Flupenthixol on 
Risky Choice
Unless noted otherwise noted, the same procedures as in 
Experiments 2 and 3 were used. After completion of lever press-
ing training, animals were subsequently trained in the risk-dis-
counting task. Animals were implanted with cannulae directed 
to the OFC (AP +3.5 mm; ML ±2.6 mm; DV -5.2; Paxinos and 
Watson, 1998).
Results
Experiment 1: Effects of Flupenthixol and 
Amphetamine on Risky Choice
In Experiment 1, the effects of flupenthixol and amphetamine 
were tested against saline (n  =  11). Results demonstrated an 
increased preference for the risky lever in amphetamine-treated 
rats (0.5 mg/kg) and a reduced preference in flupenthixol-treated 
rats (0.25 mg/kg; Figure  2). Accordingly, an ANOVA revealed a 
main effect of treatment [F(2, 20)  =  26.43, p  <  0.001] and trial 
block [F(3, 30) = 51.83, p < 0.001] and a treatment x block inter-
action [F(6, 60) = 5.16, p < 0.001]. Further analysis of data from 
amphetamine- and saline-treated animals revealed significant 
effects of treatment [F(1, 10) = 26.07, p < 0.001] and trial block [F(3, 
30) = 28.17, p < 0.001] and a treatment x block interaction [F(3, 
30) = 6.35, p < 0.01]. Inspection of data from flupenthixol- and 
saline-treated animals showed significant effects of treatment 
[F(1, 10) = 6.53, p < 0.05] and trial blocks [F(3, 30) = 53.58, p < 0.001], 
but no treatment x block interaction [F(3, 30) = 0.65, n.s.].
Animals treated with flupenthixol and amphetamine 
showed increased response latencies. An ANOVA revealed 
a main effect of treatment [F(2, 20)  =  7.87, p  <  0.01] and trial 
block [F(3, 30) = 6.06, p < 0.01] and a treatment x block interac-
tion [F(6, 60) = 9.91, p < 0.001]. An analysis of latency data from 
amphetamine- and saline-treated animals showed no treat-
ment effect [F(1, 10)  =  0.004, n.s.], a main effect of block [F(3, 
30) = 4.41, p < 0.05], and a trend for a treatment x block interac-
tion [F(3, 30) = 2.33, p = 0.09]. An inspection of data from flupen-
thixol- and saline-treated animals revealed a treatment effect 
[F(1, 10) = 20.74, p < 0.01], a main effect of block [F(3, 30) = 10.50, 
p  <  0.001] and a treatment x block interaction [F(3, 30)  =  8.36, 
p < 0.001].
Experiment 2: Effects of AcbC Flupenthixol on 
Risky Choice
Animals were trained on the risk-discounting task for 26 days 
before being implanted with guide cannulae. The location of 
infusion cannulae tips from all rats of Experiment 2 is shown 
in Figure  3; no animals were excluded because of misplaced 
cannulae. Intra-AcbC flupenthixol (15 µg, n  =  13) did not alter 
risk-based decisions (data not shown). In line with this notion, 
an ANOVA revealed no main effect of treatment [F(1, 12) = 0.76, 
n.s.], a main effect of trial block [F(3, 36) = 35.92, p < 0.001], and no 
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treatment x block interaction [F(3, 36) = 0.17, n.s.]. In addition, an 
analysis of latency data showed no main effect of treatment [F(1, 
12) = 0.10, n.s.], a main effect of block [F(3, 36) = 4.14, p < 0.05], 
and no treatment x block interaction [F(3, 36) = 0.59, n.s.].
By contrast, intra-AcbC flupenthixol (17.5 µg, n = 10) reduced 
preference for the risky lever (Figure 4). Accordingly, an ANOVA 
revealed a main effect of treatment [F(1, 9)  =  5.97, p  <  0.05] 
and trial block [F(3, 27) = 25.69, p  < 0.001], but no treatment x 
block interaction [F(3, 27)  =  0.18, n.s.]. Intra-AcbC flupenthixol 
increased response latencies. An ANOVA revealed no main 
effect of treatment [F(1, 9) = 0.66, n.s.], but a significant trial block 
[F(3, 27) = 5.09, p < 0.01] and treatment x block interaction [F(3, 
27) = 3.10, p < 0.05].
For a more detailed characterization of treatment effects, 
we also compared trial omissions and session durations after 
intra-AcbC flupenthixol vs. saline infusion. ANOVA revealed no 
treatment effects on trial omissions [vehicle, 5.7 ± 4.4; flupen-
thixol, 4.3 ± 2.2; F(1, 9)  =  0.08, n.s.] and session duration [vehi-
cle, 56.1 ± 3.7 min; flupenthixol, 55.1 ± 2.2; F(1, 9)  =  0.06, n.s.]. 
Regarding the win-stay ratios, an ANOVA revealed an almost 
significant effect of treatment [vehicle, 0.81 ± 0.05; flupenthixol, 
0.62 ± 0.11; F(1, 8) = 5.27, p = 0.05], indicating a reduced reward 
sensitivity in flupenthixol-treated rats. By contrast, an analy-
sis of lose-shift ratios revealed no treatment effect [vehicle, 
0.46 ± 0.11; flupenthixol, 0.56 ± 0.09; F(1, 9) = 0.99, n.s].
In a control experiment in experimentally naïve rats, we 
examined the effects of intra-AcbC flupenthixol (17.5  µg) on 
reward magnitude discrimination using a task variant in which 
subjects could choose between two levers that delivered either 
Figure 4. Effects of dopamine receptor blockade in the nucleus accumbens core 
(AcbC) on probabilistic choice in rats. Mean (± standard error of the mean) per-
centages of risky lever choices per session are shown for decreasing probabilities 
to obtain the risky reward within one session following intra-AcbC infusion of 
flupenthixol (17.5 µg/0.5 µl, black circles) or vehicle (0.5 µl, white circles; n = 10). 
*p < 0.05 (significant main effect of treatment).
Figure 2. Effects of amphetamine (grey symbols, 0.5 mg/kg, i.p.) and flupenthixol (black symbols, 0.25 mg/kg, i.p.) on probabilistic choice. Mean (± standard error of 
the mean) percentages of risky lever choices per session are shown across decreasing probabilities to obtain the risky reward within one session (n = 11). *p < 0.05; 
**p < 0.001 (significant main effects of treatment).
Figure 3. Cannulae placement in the nucleus accumbens. The schematic shows 
the location of microinfusion cannulae tips in the nucleus accumbens core 
(filled circles) and shell (open circles). The numbers indicate the distances from 
bregma, in millimeters.
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4 pellets with a decreasing probability of reward or 1 pellet with 
a certain reward (see Supplementary Material). Results showed 
that intra-AcbC flupenthixol (17.5 µg) did not affect reward mag-
nitude discrimination (Supplementary Figure S1).
Experiment 3: Effects of AcbS Flupenthixol on 
Risky Choice
Animals were trained on the risk-discounting task for 22 days 
before being implanted with guide cannulae. The location of 
infusion cannulae tips from all animals of Experiment 3 (n = 10) 
is shown in Figure 3. One animal was excluded due to cannulae 
misplacement, and another one failed to display risk discount-
ing and was also excluded from analyses. Results show that 
intra-AcbS flupenthixol (17.5 µg) did not alter the preference for 
the risky lever (Figure 5). An ANOVA revealed no main effect of 
treatment [F(1, 9) = 3.13, p = 0.11], but a significant effect of trial 
block [F(3, 27) = 28.39, p < 0.001], and no treatment x block inter-
action [F(3, 27) = 1.35, p = 0.3]. Of note, in these rats there was a 
subgroup (n = 4 out of 10) that, under control conditions, had a 
preference for the risky lever (≥50%) in the 12.5% trial block. In 
this subgroup, intra-AcbS flupenthixol reduced the preference 
for the risky lever. An ANOVA revealed an almost significant 
effect of treatment [F(1, 3) = 8.66, p = 0.06], a main effect of trial 
block [F(3, 9) = 5.32, p < 0.05], and a treatment x block interaction 
[F(3, 9) = 5.14, p < 0.05].
Intra-AcbS flupenthixol did not affect response latencies, trial 
omissions, or win stay/lose shift tendencies (see Supplementary 
Material).
Experiment 4: Effects of OFC Flupenthixol on 
Risky Choice
Animals were trained on the risk-discounting task for 25 days 
before being implanted with guide cannulae. Placements of 
infusion cannulae tips from all animals (n = 10) of Experiment 4 
are shown in Figure 6. As shown in Figure 7, intra-OFC infusion 
of flupenthixol (17.5 µg) did not alter the preference for the risky 
lever. Accordingly, an ANOVA revealed no main effect of treat-
ment [F(1, 9)  =  0.03, n.s.], but a significant effect of trial block 
[F(3, 27)  =  36.88, p  <  0.001], and no treatment x block interac-
tion [F(3, 27) = 0.28, n.s.]. Intra-OFC flupenthixol did not affect 
response latencies. An ANOVA revealed no main effect of treat-
ment [F(1, 9) = 1.29, n.s.], but a significant effect of trial block [F(3, 
27) = 7.69, p < 0.001], and no treatment x block interaction [F(3, 
27) = 0.29, n.s.].
Discussion
The main finding of this study is that in rats tested in a probabil-
istic choice task, the preference for a risky reward was reduced 
after an intra-AcbC D1/D2 receptor blockade, suggesting that 
DA activity in the AcbC plays a key role in promoting choices of 
risky reward.
Figure 5. Effects of dopamine receptor blockade in the nucleus accumbens shell 
(AcbS) on probabilistic choice. Mean (± standard error of the mean) percent-
ages of risky lever choices per session are shown for decreasing probabilities 
to obtain the risky reward within one session following infusion of flupenthixol 
(17.5 µg/0.5 µl, black circles,) or vehicle (0.5 µl, white circles; n = 10).
Figure 6. Cannulae placement in the orbitofrontal cortex. The schematic shows 
the location of microinfusion cannulae tips. The numbers indicate the distances 
from bregma, in millimeters.
Figure 7. Effects of dopamine receptor blockade in the orbitofrontal cortex on 
probabilistic choice. Mean (± standard error of the mean) percentages of risky 
lever choices per session are shown for decreasing probabilities to obtain the 
risky reward within one session following infusion of flupenthixol (17.5 µg/0.5 µl, 
black circles) or vehicle (0.5 µl, white circles; n = 10).
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Systemic Dopamine Manipulation and Risky Choice
In line with previous reports (e.g. Cardinal and Howes, 2005; St 
Onge and Floresco, 2009), control animals in all experiments 
showed risk discounting across within-session trial blocks with 
decreasing large-reward probabilities. In particular, as predicted 
by the value-matching law (Herrnstein, 1961), they displayed 
rational choices: they showed no preference for either the risky 
or certain lever in the neutral trial block (4 pellets at p = 0.25 vs. 
1 pellet at p = 1.0) but avoided the risky lever in the trial block 
where the large reward was most uncertain (p = 0.125).
To validate task sensitivity to experimental manipulations of 
DA activity, we examined the effects of systemic amphetamine 
and flupenthixol, two prototypical DAergic drugs with promi-
nent effects on risky choices. In line with a previous work (St 
Onge and Floresco, 2009), amphetamine (0.5 mg/kg) increased 
the preference for the risky lever when the odds of obtaining 
a larger reward decreased over a session. Conversely, ampheta-
mine decreased the preference for the risky lever when the odds 
of obtaining a larger reward increased over a session, suggest-
ing that amphetamine may impair the ability to shift preference 
away from or towards risky options upon changes in proba-
bilistic reward value (St Onge et al., 2010). By contrast, flupen-
thixol (0.25 mg/kg) reduced the preference for the risky lever and 
increased response latencies. Overall, our data are consistent 
with previous work and confirm task sensitivity to changes in 
DA activity.
Nucleus Accumbens Dopamine and Risky Choice
Flupenthixol (17.5  µg) administered to the AcbC significantly 
reduced the preference for the risky lever in Experiment 1, sug-
gesting that drug actions in the AcbC play a role in mediating 
behavioral effects of systemic flupenthixol. Drug actions into 
adjacent subregions, due to diffusion into the AcbS, could con-
tribute to the observed effects. However, because intra-AcbC 
and AcbS infusions of flupenthixol in comparable doses and 
volumes produced dissociable behavioral effects, drug spread 
across Acb subregions may be limited (Ito and Hayen, 2011).
Remarkably, microinfusion of flupenthixol into the AcbC 
reduced the preference for the risky lever across all trial blocks, 
including the initial trial block with the large reward at p = 1.0, 
a finding that points to a drug-induced general increase of risk 
aversion. Importantly, our results indicate that flupenthixol-
induced impairments of reward magnitude discrimination could 
not account for these findings. Accordingly, a large number of 
studies revealed that transient or permanent inactivation of the 
AcbC did not alter (e.g. Balleine and Killcross, 1994; Giertler et al., 
2003, 2004; Cardinal and Howes, 2005) or moderately enhanced 
(Cardinal and Cheung, 2005) reward magnitude discrimination. 
Similarly, systemic DA antagonists do not affect the perceived 
quantity of food (Martin-Iverson et al., 1987). Likewise, Acb DA 
depletion (Salamone et al., 1994, 2001; Cousins et al., 1996; Mai 
and Hauber, 2012) or intra-Acb microinfusion of DA antagonists 
(Hauber et al., 2000; Calaminus and Hauber, 2007; Stopper et al., 
2013) did not affect the ability to discriminate large from small 
rewards. Consistent with these findings, optogenetic stimula-
tion of Acb DA signaling did not influence reward magnitude–
based decisions (Saddoris et al., 2014).
While our subregion-specific analysis demonstrates that a 
blockade of D1/D2 receptors in the AcbC reduced risky choices, a 
previous receptor type–specific analysis revealed that a D1, but 
not D2, receptor blockade within the whole Acb reduced risky 
choices (Stopper et  al., 2013). Together, these findings suggest 
that AcbC D1 receptors may play a key role in regulating risk-
based decision making. Furthermore, intra-AcbC flupenthixol 
(17.5 µg) increased response latencies, a finding that is consist-
ent with the notion that the Acb and its DA input invigorate 
instrumental responding (e.g. Yun et al., 2004; Salamone et al., 
2005; Calaminus and Hauber, 2007).
In line with earlier data (e.g. Stopper et al., 2013), under vehi-
cle treatment our rats chose the risky lever in about 85% of tri-
als after receiving the risky reward in the preceding trial, while 
they shifted to the certain lever in about 35–50% of trials after 
not receiving the risky reward in the preceding trial. Intra-AcbC 
flupenthixol selectively decreased win-stay tendencies but 
left lose-shift tendencies unaltered. According to this analysis, 
reduced risky choice under flupenthixol is predominantly driven 
by an underestimated probability for a large reward re-gain 
in the subsequent trial. However, our interpretation is limited 
because this win-stay/lose-shift analysis relies on the arguable 
assumption that a given choice trial was influenced only by the 
immediately preceding choice trial and, due to data limitations, 
does not allow a separate analysis of individual within-session 
trial blocks. Contrasting with our results, reduced risky choice 
after SCH23390 injection into the whole Acb was associated 
with unaltered win-stay but enhanced lose-shift tendencies 
(Stopper et al., 2013). Of note, transient Acb inactivation (Stopper 
and Floresco, 2011) and Acb D1 receptor blockade (Stopper et al., 
2013) both reduced risky choice associated with either reduced 
win-stay or increased lose-shift tendencies. Thus, reduced risk 
taking after experimental Acb manipulations may not neces-
sarily align with uniform changes in win-stay/lose-shift ten-
dencies. Overall, our data suggest that intra-AcbC flupenthixol 
reduced risky choice and win-stay tendencies.
Results further show that intra-AcbS flupenthixol did not 
alter risk-based decision making. It is unlikely that drug dos-
ing (17.5 µg/side) was inappropriate, as this dose was behavio-
rally effective when injected into the AcbC (Experiment 2) and 
this or a moderately lower dose was behaviorally effective 
when administered to the AcbC (Naneix et al., 2009; Simmons 
and Neill, 2009; Moscarello et al., 2010). Nevertheless, we can-
not exclude the possibility that higher doses could impair risky 
choice. Remarkably, in drug-naïve rats’ D1 mRNA expression, 
but not D2 mRNA expression, in the AcbS was positively cor-
related with risk-taking in a task that involves a certain small 
reward and a large reward accompanied by variable probabili-
ties of footshock punishment (Simon et al., 2011). These findings 
imply that flupenthixol, through blocking the D1 receptor type, 
could have reduced risky choice, predominantly in risk-prone 
rats characterized by higher levels of D1 mRNA expression. Our 
data provide indirect support to this notion. In this experiment, 
there was a subgroup of rats showing risk-prone behavior under 
vehicle treatment (≥50% risky lever preference in the 12.5% trial 
block) in which flupenthixol almost significantly reduced the 
preference for the risky lever (p = 0.06). Thus, this latter finding 
leaves open the possibility of a contribution of AcbS DA activity 
in mediating risk-based decision making, possibly through D1 
receptor signaling in risk-prone rats as suggested by data from 
Simon et al. (2011).
Orbitofrontal Dopamine and Risky Choice
Intra-OFC flupenthixol did not alter risk-based decision mak-
ing or win-stay/lose-shift tendencies, an observation that might 
not be accounted for by inappropriate drug dosing. For instance, 
similar or lower doses of flupenthixol infused into the adjacent 
prelimbic cortex were behaviorally effective in related tasks 
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(Naneix et  al., 2009). However, we cannot rule out that higher 
doses could impair risky choices. Of note, previous studies using 
the same task suggest that it is the medial (Stopper et al., 2014a), 
not the most lateral part of the OFC (St Onge and Floresco, 2010), 
that mediates risk-based decision making. In our study, micro-
infusions were aimed at more ventral regions of the OFC, shown 
to mediate behavioral flexibility in instrumental tasks through 
DA D1-, D2-, and N-methyl-D-aspartate-receptor-mediated sign-
aling (Bohn et al., 2003; Calaminus and Hauber, 2008). In view of 
the drug spread observed after prefrontal microinfusion of the 
radio-labeled DA D1 receptor antagonist SCH23390 in the same 
volume (0.5 µl) as used here (Granon et  al., 2000), our flupen-
thixol microinfusions should have targeted not only lateral and 
ventral but also medial OFC regions, though at somewhat more 
posterior locations, as in the study by Stopper et  al. (2014a). 
A  recent study revealed that, by increasing reward sensitivity 
and behavioral flexibility, OFC DA depletion improved the ability 
of marmosets to learn a visual discrimination task that involved 
ambiguous feedback (Clarke et al., 2014). Furthermore, there is 
correlative evidence for a role of OFC DA signaling in modulating 
decision making, since greater D2 mRNA expression in the OFC 
predicts higher risk preference (Simon et al., 2011). However, our 
findings provide no evidence for a role of OFC DA activity in risk-
related decision making.
Brain Dopamine and Risky Choice
The main finding of our study is that intra-AcbC D1/D2 activ-
ity plays a critical role in promoting choice of the risky reward. 
While it is clear that D1/D2 receptor-mediated signals must sup-
port risky choice by influencing the activity of AcbC neurons, the 
nature of this influence is difficult to assess. DA neurons operate 
in distinct temporal modes: they display responses across vary-
ing timescales, including fast phasic changes of DA release on 
a time scale of seconds and slower phasic changes in a range 
of minutes, while tonic levels of DA provide a DA receptor tone 
(for review, see Schultz, 2007; Hauber, 2010). Intra-AcbC flupen-
thixol likely disrupted phasic as well as tonic DA signaling, thus 
a blockade of one or more of these informational and modula-
tory DA signals could underlie the shift in risky choices seen 
here. For instance, a subset of DA neurons display slow and 
moderate activation that increases gradually during the interval 
between a reward-predicting stimulus and reward delivery and 
varies monotonically with risk (Fiorillo et  al., 2003). However, 
due to its low magnitude, this DA risk signal probably induces 
only a relatively low DA release that might predominantly acti-
vate D2 receptors that are mostly in a high affinity state, but not 
the low affinity D1 receptors (Schultz, 2010). Given that intra-
AcbC D1 receptor-mediated signaling may be particularly rel-
evant to support the risky choices analyzed here, a contribution 
of this DA risk signal to promote risk seeking seems therefore 
less likely. A recent study in rats performing a risky choice task 
revealed that phasic DA signals provide feedback on whether 
prior actions were rewarded, signals that are critical to update 
risk-related decision-making policies (Stopper et  al., 2014b). 
As intra-AcbC flupenthixol might have blocked the phasic DA 
signals that provide feedback both on risky reward and cer-
tain reward actions, it is difficult to see how such a drug effect 
would produce the observed preference for the certain lever. Of 
note, our rats subjected to AcbC flupenthixol were able to track 
increasing risks associated with the large reward but, impor-
tantly, displayed a generally reduced preference for the risky 
lever across all trial blocks, including the initial trial block (4 pel-
lets at p = 1.0). This suggests that AcbC flupenthixol produced a 
general bias away from the lever known to provide an initially 
certain large reward but that becomes increasingly risky within 
a session. In other words, intra-AcbC flupenthixol could have 
rendered animals more sensitive to the known costs of the risky 
response option. Remarkably, AcbC flupenthixol failed to mimic 
the effects of systemic flupenthixol: rats that received systemic 
flupenthixol displayed a high preference for the risky lever in 
the initial trial block but not later trial blocks, suggesting that 
they may be more sensitive to changes in risk.
Thus, AcbC activity in intact rats could provide information 
about the overall cost-benefit ratios of the available response 
options in more general terms. In line with this notion, recent 
microdialysis studies revealed that slow fluctuations of tonic 
Acb DA in the range of minutes incorporate multiple types of 
information, such as reward availability and risk (Stopper et al., 
2013). However, it is important to note that the flupenthixol-
induced shift in risky choices could not only reflect a blockade 
of such informational DA signals but a blockade of modulating 
DA signals as well. Tonic DA activity provides an enabling influ-
ence (Schultz, 2007) and modulates excitatory input from the 
mPFC, OFC, and BLA, regions that are critical in mediating risk-
based decision making (Mobini et al., 2002; Ghods-Sharifi et al., 
2009; St Onge and Floresco, 2010). Accordingly, the flupenthixol-
induced bias toward the safe response option could also reflect 
a dysregulated integration of afferent information from cortical 
and limbic regions in the AcbC. Moreover, the mPFC, BLA, and 
OFC each receive prominent input from midbrain DA neurons 
that subserve action selection. For instance, DA signals in the 
BLA support reward-directed action (Berglind et al., 2006): how-
ever, their role in risk-based decision making is still unknown. 
By contrast, DA signals in the mPFC govern risky choice by 
complementary actions on D1 and D2 receptors (St Onge et al., 
2011). Here we show that DA signals in the OFC, though sup-
porting flexible reward-directed responding (e.g. Calaminus and 
Hauber, 2008; Takahashi et al., 2009; Clarke et al., 2014), may not 
modulate risky choices. Thus, the mPFC and OFC are essential 
components of a neural circuit mediating risk-based decisions; 
however, processes in the OFC that subserve risky decisions do 
not rely on intact DA input, other than those in the mPFC.
Conclusions
Here we show that, among the terminal areas of DA projections 
investigated, DA activity in the AcbC plays a critical role in pro-
moting the choice of the risky reward. The observed pattern of 
responding suggests that intra-AcbC DA D1/D2 receptor signaling 
does not support the ability to track increasing risk associated 
with the large reward but invigorates responding and inclines 
rats to choose a response option known to be associated with 
increasing risk-related costs. This conclusion is consistent with 
the largely congruent concepts that AcbC DA activity invigorates 
reward seeking (Nicola, 2007), mediates a “go” response toward 
motivationally-relevant stimuli (Floresco, 2015), or serves as a 
bridge that enables animals to traverse the distance that sepa-
rates them from reward in multiple dimensions, including risk or 
effort (Salamone and Correa, 2012). In addition, our data provide 
support to the idea that drug actions in the AcbC play a major role 
in mediating abnormal risk-related decision making in humans 
under DA agonist therapy (Cools et al., 2003; Gallagher et al., 2007).
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